Does Rallies show live market data for DARE?

Rallies combines live market context with ticker research for DARE, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

DARE (Dare Bioscience, Inc. Common Stock) Stock Analysis

Dare Bioscience, Inc. Common Stock (DARE) is a publicly traded Healthcare sector company. As of May 21, 2026, DARE trades at $2.39 with a market cap of $31.61M and a P/E ratio of -2.46. DARE moved +5.11% today. Year to date, DARE is +17.09%; over the trailing twelve months it is -19.38%. Its 52-week range spans $1.27 to $9.19. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces DARE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest DARE stock research?

Dare Bioscience, Inc. Common Stock (DARE) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. DARE moved +5.11% today. Analyst consensus is buy.

DARE Key Metrics

Key financial metrics for DARE
Metric	Value
Price	$2.39
Market Cap	$31.61M
P/E Ratio	-2.46
EPS	$-0.96
Dividend Yield	0.00%
52-Week High	$9.19
52-Week Low	$1.27
Volume	287.99K
Avg Volume	0
Revenue (TTM)	$1.16M
Net Income	$-12.02M
Gross Margin	0.00%

Latest DARE News

Dare Bioscience to Launch FloraSync LF5 in June, Seeks Additional Funding — May 15, 2026
Daré Bioscience Achieves Second Positive Ovaprene DSMB Review, Eyes June Product Revenue — May 14, 2026
Daré Bioscience’s Ovaprene Trial Yields 9% Pregnancy Rate, 12% Discontinuations — May 12, 2026
Daré Bioscience Launches DARE to PLAY Cream, Eyes Q2 2026 Revenue — Mar 26, 2026
Dare Bioscience Forecasts $0.38M Q4 Revenue, Sees 690% Price Upside — Mar 25, 2026

DARE Analyst Consensus

2 analysts cover DARE: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.

Common questions about DARE

What can I research for DARE on Rallies?: Dare Bioscience, Inc. Common Stock (DARE) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. DARE moved +5.11% today. Analyst consensus is buy.
Does Rallies show live market data for DARE?: Rallies combines live market context with ticker research for DARE, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.